Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.40 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214459 | 0.89 | NPSR1 (0.56) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL11742099 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL9048698 | 0.83 | GLO1 (0.67) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL28285733 | 0.83 | GLO1 (0.67) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL9048705 | 0.83 | GLO1 (0.67) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL23394794 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL12180594 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL1369380 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL11655592 | 0.82 | NPSR1 (0.48) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL11655595 | 0.82 | NPSR1 (0.48) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2150544-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8207328-B2 | Lactosamine derivatives | GLYCOM APS (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-1996602-B8 | NOVEL LACTOSAMINE DERIVATIVES | GLYCOM AS (DK) | 2012-03-14 | — | — | EP | disclosed |
| US-8063066-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-1996602-A1 | NOVEL LACTOSAMINE DERIVATIVES | Glycom APS (DK) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008115890-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007104311-A1 | NOVEL LACTOSAMINE DERIVATIVES | GLYCOM APS (DK) | 2007-09-20 | — | — | WO | disclosed |
| US-4665218-A | Method for the preparation of alkoxymethylene compounds of acetic esters and substituted acetic esters | DYNAMIT NOBEL AG (DE) | 1987-05-12 | — | — | US | disclosed |
| US-4649220-A | Method for performing organic reactions in silicone oils | DYNAMIT NOBEL AG (DE) | 1987-03-10 | — | — | US | disclosed |
| US-4109087-A | CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-22 | — | — | US | disclosed |
| US-4109091-A | CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-22 | — | — | US | disclosed |
| US-4072679-A | CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-02-07 | — | — | US | disclosed |
| US-4058553-A | Method of preparing alkoxymethylenemalonic acid esters | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | NPSR1 3608/4885GLO1 2085/4885ALDH1A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.